{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ilyinskii PO"],"funding":["NIAID NIH HHS"],"pagination":["2177-85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2440663"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(18)"],"pubmed_abstract":["Targeting viral antigens for proteosomal degradation has previously been proposed as a means for immunogenicity augmentation. However, utilization of modified unstable antigens may be insufficient for potent T-cell cross-presentation by APCs, a mechanism that requires high levels of the antigenic protein. Therefore, we hypothesized that a recombinant vaccine utilizing a combination of proteosome-sensitive and proteosome-resistant versions of an antigen in a prime-boost regimen may provide the most efficient CTL response. To address this hypothesis, we utilized conserved proteosome-resistant influenza A virus proteins M1 and NS1. Unstable versions of these polypeptides were constructed by destroying their 3D structure via truncations or short insertions into predicted alpha-helical structur"],"journal":["Vaccine"],"pubmed_title":["Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response."],"pmcid":["PMC2440663"],"funding_grant_id":["R43 AI063634","R43 AI063634-01","R43 AI063634-02"],"pubmed_authors":["Meriin AB","Thoidis G","Gabai VL","Shneider AM","Ilyinskii PO","Zhirnov OP"],"additional_accession":[]},"is_claimable":false,"name":"Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response.","description":"Targeting viral antigens for proteosomal degradation has previously been proposed as a means for immunogenicity augmentation. However, utilization of modified unstable antigens may be insufficient for potent T-cell cross-presentation by APCs, a mechanism that requires high levels of the antigenic protein. Therefore, we hypothesized that a recombinant vaccine utilizing a combination of proteosome-sensitive and proteosome-resistant versions of an antigen in a prime-boost regimen may provide the most efficient CTL response. To address this hypothesis, we utilized conserved proteosome-resistant influenza A virus proteins M1 and NS1. Unstable versions of these polypeptides were constructed by destroying their 3D structure via truncations or short insertions into predicted alpha-helical structur","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008 Apr","modification":"2025-06-01T01:07:17.098Z","creation":"2019-03-27T00:15:36Z"},"accession":"S-EPMC2440663","cross_references":{"pubmed":["18400345"],"doi":["10.1016/j.vaccine.2008.02.050"]}}